Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) EBT Margin (2016 - 2025)

Historic EBT Margin for Pharma-Bio Serv (PBSV) over the last 16 years, with Q4 2025 value amounting to 0.2%.

  • Pharma-Bio Serv's EBT Margin rose 8300.0% to 0.2% in Q4 2025 from the same period last year, while for Oct 2025 it was 1.05%, marking a year-over-year increase of 69000.0%. This contributed to the annual value of 1.05% for FY2025, which is 69000.0% up from last year.
  • Per Pharma-Bio Serv's latest filing, its EBT Margin stood at 0.2% for Q4 2025, which was up 8300.0% from 10.65% recorded in Q3 2025.
  • Pharma-Bio Serv's 5-year EBT Margin high stood at 46.38% for Q3 2021, and its period low was 85.7% during Q4 2021.
  • Over the past 5 years, Pharma-Bio Serv's median EBT Margin value was 4.58% (recorded in 2022), while the average stood at 0.09%.
  • Per our database at Business Quant, Pharma-Bio Serv's EBT Margin plummeted by -887300bps in 2021 and then skyrocketed by 906800bps in 2022.
  • Pharma-Bio Serv's EBT Margin (Quarter) stood at 85.7% in 2021, then skyrocketed by 106bps to 4.98% in 2022, then crashed by -127bps to 1.33% in 2023, then soared by 52bps to 0.64% in 2024, then skyrocketed by 131bps to 0.2% in 2025.
  • Its EBT Margin was 0.2% in Q4 2025, compared to 10.65% in Q3 2025 and 4.17% in Q2 2025.